Glenmark Pharmaceuticals Recalls Diltiazem Hydrochloride Due to Nitrosamine Impurity, Raising Supply Chain Concerns
Glenmark Pharmaceuticals Inc., USA has initiated a Class II nationwide recall of 4,704 bottles of Diltiazem Hydrochloride Extended-Release Capsules due to cGMP deviations. The recall, D-0097-2025, stems from N-nitroso-Desmethyl-Diltiazem impurity levels exceeding FDA interim limits. This event underscores persistent nitrosamine risks and highlights critical cGMP compliance challenges for pharmaceutical manufacturers, impacting supply chain reliability and regulatory standing.
FDA Class II Recall: Diltiazem Hydrochloride Impurity Exceeds Limits
Glenmark Pharmaceuticals Inc., USA has initiated a Class II voluntary recall, designated D-0097-2025, for specific lots of Diltiazem Hydrochloride Extended-Release Capsules, USP 90mg. This action, commenced on November 1, 2024, targets 4,704 bottles distributed nationwide across the USA. The critical reason for this recall is identified as cGMP deviations, specifically the presence of N-nitroso-Desmethyl-Diltiazem impurity at levels exceeding the FDA's recommended interim limits. This means that procurement directors and regulatory affairs heads must immediately assess their inventory and supply lines for Diltiazem Hydrochloride, particularly those sourced from Glenmark or its manufacturing partners. The Class II classification indicates that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. For business development executives, this highlights the paramount importance of robust quality control and compliance in partnership evaluations, as such deviations can severely impact product viability and market access.
Commercial Impact: Diltiazem Hydrochloride Supply Disruption
The recall impacts Diltiazem Hydrochloride Extended-Release Capsules, USP 90mg, a critical medication for cardiovascular conditions, manufactured by Glenmark Pharmaceuticals Limited in Pithampur, Madhya Pradesh, India, for Northstar Rx LLC. The affected product, identified by NDC 16714-554-01, includes Lot #: 17222452 with an Expiration Date of November 30, 2024, and Lot #: 17230607 with an Expiration Date of February 28, 2025. With 4,704 bottles withdrawn from the U.S. market, supply chain VPs must evaluate potential short-term availability impacts for this specific dosage and formulation. While the quantity may not represent a catastrophic market shortage, any disruption to an essential drug like Diltiazem Hydrochloride necessitates immediate contingency planning. Procurement teams should verify their current stock levels, identify any affected lots, and proactively engage with alternative suppliers to ensure continuity of patient care and mitigate business risks associated with supply chain instability.
Persistent Nitrosamine Challenges in Pharmaceutical Manufacturing
The detection of N-nitroso-Desmethyl-Diltiazem impurity above FDA interim limits underscores the ongoing industry-wide challenge with nitrosamine contamination in active pharmaceutical ingredients (APIs) and finished drug products. This specific impurity, a potential genotoxic carcinogen, has been a focal point of global regulatory scrutiny since 2018. For regulatory affairs heads, this event reinforces the need for rigorous risk assessments and control strategies for nitrosamines, extending beyond the initial wave of sartans and ranitidine. It means that manufacturers, including those producing Diltiazem Hydrochloride under ANDA212317, must continuously review their manufacturing processes, raw material sourcing, and impurity testing methodologies to comply with evolving FDA expectations. Business development executives considering partnerships must scrutinize potential collaborators' nitrosamine control programs, as inadequate measures pose significant regulatory and reputational risks.
Broader Industry Context: Systemic Quality Control Risks
This Glenmark recall is not an isolated incident but rather indicative of broader systemic challenges within the pharmaceutical manufacturing sector. Recent parallel events highlight a pattern of cGMP deviations leading to Class I and Class II recalls across the industry. For instance, Pfizer faced Class I recalls for Bleomycin Injection and Sodium Bicarbonate Injection due to glass particulate matter. Sandoz experienced a Class II recall for Enoxaparin Sodium due to temperature excursion risks, while Teva Pharmaceuticals' Warfarin Sodium and Allergan's ARMOUR THYROID were also impacted by Cardinal Healthcare's temperature excursion cGMP deviations. These incidents collectively signal persistent vulnerabilities in quality control, process validation, and supply chain integrity. For supply chain VPs, this means that comprehensive risk management strategies must extend beyond individual supplier audits to encompass broader industry trends and shared logistics partners, ensuring resilience against diverse cGMP-related failures.
Strategic Implications for Procurement and Regulatory Compliance
For procurement directors, the Glenmark Diltiazem Hydrochloride recall necessitates a critical review of supplier qualification processes, particularly for generic drug products manufactured offshore. The presence of nitrosamine impurities demands enhanced due diligence, including detailed audits of API and finished product manufacturers' impurity profiles and control strategies. Regulatory affairs heads must ensure that their organizations are fully aligned with current FDA guidance on nitrosamine risk assessment and mitigation, proactively updating regulatory submissions and quality management systems. This event underscores the commercial imperative of supply chain diversification; relying on a single source, especially for essential medications, exposes businesses to significant operational and reputational risks when quality issues arise. Business development executives should leverage these insights to identify and partner with manufacturers demonstrating superior cGMP compliance and robust quality assurance frameworks, thereby safeguarding future product launches and market penetration.
Outlook for Glenmark and Future Compliance Expectations
The 'Ongoing' status of this recall indicates that Glenmark Pharmaceuticals Inc., USA, and its manufacturing arm, Glenmark Pharmaceuticals Limited in India, are actively managing the situation. As a voluntary, firm-initiated recall, Glenmark is expected to conduct a thorough root cause analysis to identify the origin of the N-nitroso-Desmethyl-Diltiazem impurity and implement comprehensive corrective and preventive actions (CAPA). For procurement directors, this means closely monitoring Glenmark's remediation efforts and FDA's subsequent oversight. Future regulatory actions, such as potential Warning Letters or Import Alerts, could arise if the FDA deems the CAPA insufficient or if systemic issues persist at the Pithampur facility. Supply chain VPs should consider the long-term implications for Glenmark's ability to consistently supply products, factoring in potential delays in future product approvals or increased scrutiny on their entire portfolio. Proactive engagement with Glenmark to understand their remediation plan is crucial for managing future supply risks.